KBY Biotech Indexv0.0.34
Search
← Pipeline|HOV-IIT-284

HOV-IIT-284

Phase 1
By HOVON
Source: Trial-derived·Trials: 1
Modality
Small Molecule
MOA
SGLT2i
Target
CD19
Pathway
Epigenetic
Bladder Ca
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
Jan 2022
Phase 1Current
NCT03818864
1,557 pts·Bladder Ca
2022-01→TBD·Recruiting
1,557 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2022
P1
Recruit…
Recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03818864Phase 1Bladder CaRecruiting1557CR
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-8662PfizerNDA/BLACD19GLP-1ag
JNJ-8232Johnson & JohnsonNDA/BLAMALT1SGLT2i
NVS-6974NovartisPreclinicalCD19HPK1i
VoxarasimodMerck & CoPhase 1/2CD19AuroraAi
BemalucimabBristol-Myers SquibbPhase 1/2AβSGLT2i
BAY-3308BayerPhase 1ALKSGLT2i
MRN-8225ModernaPreclinicalTNFαSGLT2i
MotazanubrutinibBiogenPreclinicalCD38SGLT2i
ALN-5628AlnylamPhase 1/2APOC3SGLT2i
TirarelsinTG TherapeuticsNDA/BLACD19IL-17i